slu-pp-332 and retatrutide together SLU-PP-332 marketing raises concerns over

Abbreviations AEs: Adverse events NAEs: Neurological adverse events FDA: The Food and Drug Administration FAERS: The FDA Adverse Event Reporting System GLP-1 RAs: Glucagon-like peptide-1 receptor agonists ADRs: Adverse drug reactions PTs: Preferred Terms SOCs: System Organ Classes IQR: Interquartile range ROR: Reporting odds ratio CI: Confidence interval PRR: Proportional reporting ratio BCPNN: Bayesian Confidence Propagation Neural Network EBGM: Empirical Bayesian geometric mean EBGM05: The lower limit of 95% CI of EBGM IC: Information component IC025: The lower limit of 95% CI of the IC VANs: Vagal afferent neurons T2DM: Type 2 diabetes mellitus OR: Odds ratios References Targher, G., Mantovani, A

Moreover, the infiltration of inflammatory cells was observed in the liver of NASH mice, which was attenuated following the administration of cinchonine

[PMID: 42490155] PubMed record related to this compound for laboratory literature review

The highest risk was in semaglutide (HR=1.39), then liraglutide (HR=1.25)

This is particularly relevant given the increasing combined use of these effective drug classes.1011 Biological mechanisms The associations observed with the GLP-1 receptor agonist-SGLT-2 inhibitor combination in this study can be attributed to an additive effect resulting from their different yet complementary mechanisms of action

The goal is to give you an honest picture so you can decide, with your provider, whether its worth your time